These findings, taken together with previous studies demonstrating that normal ABL1 kinase not only counteracts the BCR::ABL1 oncogenic functions but also sensitizes CML cells to TKIs [17, 49] suggest that ABL1 could be a crucial therapeutic target to be further explored. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.